CL2014002523A1 - Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras - Google Patents

Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras

Info

Publication number
CL2014002523A1
CL2014002523A1 CL2014002523A CL2014002523A CL2014002523A1 CL 2014002523 A1 CL2014002523 A1 CL 2014002523A1 CL 2014002523 A CL2014002523 A CL 2014002523A CL 2014002523 A CL2014002523 A CL 2014002523A CL 2014002523 A1 CL2014002523 A1 CL 2014002523A1
Authority
CL
Chile
Prior art keywords
esophagitis
prematurity
retinopathy
piperidine
pyridine
Prior art date
Application number
CL2014002523A
Other languages
English (en)
Spanish (es)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2014002523A1 publication Critical patent/CL2014002523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
CL2014002523A 2012-04-03 2014-09-24 Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras CL2014002523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03

Publications (1)

Publication Number Publication Date
CL2014002523A1 true CL2014002523A1 (es) 2015-01-23

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002523A CL2014002523A1 (es) 2012-04-03 2014-09-24 Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras

Country Status (28)

Country Link
US (5) US20130261153A1 (OSRAM)
EP (3) EP2833884B1 (OSRAM)
JP (2) JP2015512432A (OSRAM)
KR (5) KR20210063481A (OSRAM)
CN (2) CN104220073A (OSRAM)
AU (1) AU2013245027B2 (OSRAM)
BR (1) BR112014023795B1 (OSRAM)
CA (1) CA2869269C (OSRAM)
CL (1) CL2014002523A1 (OSRAM)
CY (1) CY1123222T1 (OSRAM)
DK (1) DK2833884T3 (OSRAM)
EA (1) EA032263B1 (OSRAM)
ES (2) ES2811554T3 (OSRAM)
HR (1) HRP20201165T1 (OSRAM)
HU (1) HUE051648T2 (OSRAM)
IL (1) IL234262A (OSRAM)
IN (1) IN2014DN06989A (OSRAM)
LT (1) LT2833884T (OSRAM)
MX (1) MX2014011786A (OSRAM)
NZ (1) NZ628882A (OSRAM)
PH (1) PH12014502239A1 (OSRAM)
PL (1) PL2833884T3 (OSRAM)
PT (1) PT2833884T (OSRAM)
RS (1) RS60665B1 (OSRAM)
SI (1) SI2833884T1 (OSRAM)
SM (1) SMT202000499T1 (OSRAM)
WO (1) WO2013149986A1 (OSRAM)
ZA (1) ZA201406082B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN109310486B (zh) 2016-11-24 2021-07-02 雾岛精工株式会社 齿列矫正器和齿列矫正器的安装方法
JP2020513005A (ja) 2017-04-05 2020-04-30 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
ES2950453T3 (es) * 2017-04-05 2023-10-10 Alkahest Inc Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
SG11202002437VA (en) * 2017-10-13 2020-04-29 Alkahest Inc Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
CN112469439A (zh) 2018-05-15 2021-03-09 万能溶剂有限公司 用白三烯a4水解酶调节剂治疗衰老相关性疾病
JP7528065B2 (ja) * 2018-09-26 2024-08-05 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
WO2021252647A1 (en) * 2020-06-11 2021-12-16 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
ATE414151T1 (de) * 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
BR112014023795B1 (pt) 2021-09-08
EP4389217A2 (en) 2024-06-26
EP4389217A3 (en) 2024-08-28
US20200375971A1 (en) 2020-12-03
LT2833884T (lt) 2020-09-10
JP2018080183A (ja) 2018-05-24
HRP20201165T1 (hr) 2020-12-11
CY1123222T1 (el) 2021-10-29
HUE051648T2 (hu) 2021-03-29
IN2014DN06989A (OSRAM) 2015-04-10
EP2833884B1 (en) 2020-05-20
EP3763369A1 (en) 2021-01-13
PL2833884T3 (pl) 2020-11-02
DK2833884T3 (da) 2020-08-10
ES2987267T3 (es) 2024-11-14
RS60665B1 (sr) 2020-09-30
IL234262A (en) 2017-10-31
BR112014023795A2 (OSRAM) 2017-06-20
CA2869269C (en) 2020-06-30
KR20220132012A (ko) 2022-09-29
PH12014502239A1 (en) 2014-12-15
EA032263B1 (ru) 2019-05-31
WO2013149986A1 (en) 2013-10-10
PT2833884T (pt) 2020-08-26
US20160081998A1 (en) 2016-03-24
CA2869269A1 (en) 2013-10-10
EA201401083A1 (ru) 2015-03-31
NZ628882A (en) 2016-05-27
JP2015512432A (ja) 2015-04-27
MX2014011786A (es) 2014-12-05
KR20140144200A (ko) 2014-12-18
EP2833884A1 (en) 2015-02-11
ZA201406082B (en) 2019-01-30
KR20200044988A (ko) 2020-04-29
US20130261153A1 (en) 2013-10-03
AU2013245027A1 (en) 2014-09-11
AU2013245027B2 (en) 2017-10-12
EP3763369B1 (en) 2024-02-28
BR112014023795A8 (pt) 2017-10-10
US20170319567A1 (en) 2017-11-09
CN110384699A (zh) 2019-10-29
CN104220073A (zh) 2014-12-17
ES2811554T3 (es) 2021-03-12
KR20210063481A (ko) 2021-06-01
SI2833884T1 (sl) 2020-10-30
SMT202000499T1 (it) 2020-11-10
KR20250133980A (ko) 2025-09-09
US20150099783A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
CL2014002523A1 (es) Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
CL2016000060A1 (es) Derivados piperidinil indol y su uso como inhibidores factor de complemento b.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
GB2516561B (en) Compositions, formulations and methods for treating ocular diseases
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3350180T3 (da) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-onderivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af cancer
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
PL3069720T3 (pl) Kompozycja farmaceutyczna zawierająca pochodne glutarimidu i jej zastosowanie w leczeniu chorób eozynofilowych
KR102183910B9 (ko) 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
CL2015002835A1 (es) Nuevos derivados de piridina
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
CL2012003637A1 (es) Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.